Evidence map›Paper›PMID 40551696›Full record

ArticleCurrent medical imaging2025

Development of a Radiomic-clinical Nomogram for Prediction of Survival in Patients with Nasal Extranodal Natural Killer/T-cell Lymphoma

Limin Chen, Zhao Wang, Xiaojie Fang, Mingjie Yu, Haimei Ye, Lujun Han, Ying Tian, Chengcheng Guo, Huang He

Abstract read
In one paragraph

Article in Current medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Limin ChenDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Zhao WangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Xiaojie FangDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Mingjie YuDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Haimei YeDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Lujun HanDepartment of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Ying TianDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Chengcheng GuoDepartment of Neurosurgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.
Huang HeDepartment of Medical Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionAn accurate and reliable prognostic model for Nasal Extranodal Natural Killer/T-cell Lymphoma (ENKTL) is critical for survival outcomes and personalized therapy. Currently, there is no Magnetic Resonance Imaging (MRI)- based radiomics analysis in the prognosis model for nasal ENKTL patients.

objectiveWe aim to explore the value of MRI-based radiomics signature in the prognosis of patients with nasal ENKTL.

methodsA total of 159 nasal ENKTL patients were enrolled and divided into a training cohort (n=81) and a validation cohort (n=78) randomly. Radiomics features from pretreatment MRI examination were extracted, respectively. Then two-sample t-test and Least Absolute Shrinkage and Selection Operator (LASSO) regression were used to select the radiomics signatures and establish the Rad-score. Univariate and multivariate Cox proportional hazards regression models were used to investigate the prognostic value of baseline clinical features and establish clinical models. A radiomics nomogram based on the Rad-score and clinical features was constructed to predict Overall Survival (OS). The predictive efficacy of the three models was evaluated in two cohorts.

resultsA total of 1,345 features were extracted from T2-weighted (T2-w) and Contrast-enhanced T1-weighted (CET1-w) images, respectively, and 1,037 features with Intraclass Correlation Coefficient (ICC) >0.7 were selected. Ultimately, 20 features were chosen to construct the Rad-score, which showed a significant association with OS. The C-indexes of the Rad-score were 0.733 (95% confidence interval (CI): 0.645 to 0.816) and 0.824 (95% CI: 0.766-0.882), respectively, in training and validation cohorts. Through the univariate and multivariate analyses, three independent risk factors for OS were identified: Rad-score (HR: 10.962, 95% CI: 3.417-35.167, P <0.001), lactate dehydrogenase (LDH) level (HR: 3.009, 95% CI: 1.128-8.510, P = 0.028) and distant lymph-node involvement (HR: 2.966, 95% CI: 1.015-8.664, P = 0.047). Patients with distal lymph node involvement and LDH level before treatment were included in the clinical model, which achieved a C-index of 0.707 (95% CI: 0.600–0.814) in the training cohort and 0.635 (95% CI: 0.527–0.743) in the validation cohort. We integrated the Rad-score and clinical variables to establish a radiomics nomogram, which exhibited a satisfactory prediction performance with the C-indexes of 0.849(95% CI: 0.781-0.917) and 0.931 (95% CI: 0.882-0.980) in two cohorts, respectively. The radiomics nomogram was more accurate in predicting OS in patients with nasal ENKTL than the other two models. Based on the radiomics nomogram, patients were categorized into low-risk and high-risk groups in two cohorts (P all < 0.05). The high-risk group defined by this nomogram exhibited a shorter OS.

conclusionThe Rad-score was significantly correlated with OS for nasal ENKTL patients. Moreover, the MRI-based radiomics nomogram could be used for risk stratification and might guide individual treatment decisions.

Indexed as

Lymphoma, Extranodal NK-T-CellMagnetic Resonance ImagingNomogramsNose NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedPrognosisRadiomicsRetrospective StudiesENKTLIntraclass Correlation CoefficientLactate dehydrogenaseMagnetic resonance imagingPrognosis.Radiomics

Identifiers

PMID40551696
PMCPMC13176757

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.